Isotopes

Already a leader in the production of lutetium-177 for targeted cancer therapy, the international collaboration of Bruce Power, Isogen (a Kinectrics and Framatome company), Gamzook’aamin Aakoziwin (partnership with the Saugeen Ojbiway Nation), and ITM Isotope Technologies Munich SE (ITM), has … Read more

Beginning from a position of strength as one of the largest suppliers of cobalt-60, Bruce Power and Nordion are working on increasing their production of the medical isotope to meet the increasing demands of the world market. The companies will … Read more

The Government of Canada has announced its intent to lead the fight against cancer at home and around the world with funding announced today that will support the development of a medical isotope ecosystem in Canada. The partnership includes Indigenous … Read more

February 4 is World Cancer Day and one of its main themes is imagining a world in which millions of cancer deaths are prevented and access to life-saving cancer treatment is equitable for all. Bruce Power supports the goals of … Read more

An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company) and ITM Isotope Technologies Munich SE (ITM), announced today the commencement of commercial production of lutetium-177.    The announcement was celebrated at ITM’s headquarters in Munich, Germany, along … Read more

Bruce Power announced today that it has entered into a Memorandum of Understanding (MOU) with Boston Scientific to explore the feasibility of producing cancer-fighting yttrium-90 (Y-90) in its reactors. The company, already a leading producer of cobalt-60, which is used … Read more

Bruce Power has successfully completed another harvest of life-saving Cobalt-60, continuing as a world leader in the production of this critical medical isotope.  “Bruce Power continues to be a major supplier of Cobalt-60, and now more than ever the world’s … Read more

Building on the success of the new Isotope Production System (IPS) installed in the Unit 7 reactor, Bruce Power and Isogen (a partnership between Kinectrics and Framatome), are examining the feasibility of producing yttrium-90, used as a targeted liver cancer … Read more

First-of-a-kind Isotope Production System continues to progress towards commercial, industrial-scale production of medical isotopes for cancer therapeutics An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company), and ITM Isotope Technologies Munich SE (ITM), announced today a milestone … Read more